Eli Lilly and Company (LLY) Shares are Up 0.72%

Eli Lilly and Company (LLY) : Traders are bullish on Eli Lilly and Company (LLY) as it has outperformed the S&P 500 by a wide margin of 1.73% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.18%, relative to the S&P 500. The stock has risen by 0.72% in the past week indicating that the buyers are active at lower levels, but the stock is down -0.33% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 0.35% and the 50-Day Moving Average is 1.23%.The 200 Day SMA reached 2.45% Eli Lilly and Company is up 7.37% in the last 3-month period. Year-to-Date the stock performance stands at -4.6%.


Eli Lilly and Company (LLY) : The consensus price target for Eli Lilly and Company (LLY) is $95.67 for the short term with a standard deviation of $16.34. The most optimist securities analyst among the 12 who monitor the stock believes that the stock can reach $116, however, the pessimist price target for the company is $55.

For the current week, the company shares have a recommendation consensus of Buy. Eli Lilly and Company (NYSE:LLY): stock was range-bound between the intraday low of $78.17 and the intraday high of $78.91 after having opened at $78.7 on Fridays session. The stock finally closed in the red at $78.7, a loss of -0.03%. The stock remained in the red for the whole trading day. The total traded volume was 4,255,102 shares. The stock failed to cross $78.91 in Fridays trading. The stocks closing price on Thursday was $78.82.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.